MENU
MTSR
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Metsera (MTSR) Ownership - Who owns Metsera?

Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions... Show more

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
3.81B
P/E Ratio
N/A
Total Cash
530.92M
Projected Growth
N/A
Total Debt
1.06M
Revenue
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
5.05
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price

Fundamentals

MTSR
Capitalization
3.81B
P/E Ratio
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
531M
Total Cash/Share
5.05
Total Debt
1.06M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
449M
P/B Ratio
8.49
Cash Flow
N/A
Earnings
-2.93
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
1K
Current Ratio
5.26
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-316.25M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-48.12
Shares Held By Institutions
6.41B
Shares Outstanding - Current
105M
Total Liabilities
190M
Total Volume MTD
N/A
Value
N/A
Gain YTD
N/A
View a ticker or compare two or three
MTSR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. MTSR showed earnings on July 28, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details